Last reviewed · How we verify
CP-690,550 (tofacitinib)
Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Ulcerative colitis, Polyarticular course juvenile idiopathic arthritis.
At a glance
| Generic name | CP-690,550 (tofacitinib) |
|---|---|
| Also known as | Matching placebo to tofacitinib (same tablet or solution as the active arm). |
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK3, JAK2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Tofacitinib selectively inhibits JAK1 and JAK3 (and to a lesser extent JAK2), which are intracellular kinases critical for signal transduction downstream of cytokine receptors including IL-2, IL-7, and IL-15. By blocking JAK-STAT signaling, the drug suppresses T-cell proliferation and reduces production of pro-inflammatory cytokines, thereby dampening the adaptive immune response in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
- Polyarticular course juvenile idiopathic arthritis
- Psoriasis
- Atopic dermatitis
Common side effects
- Upper respiratory tract infection
- Diarrhea
- Headache
- Elevated cholesterol
- Increased creatinine
- Herpes zoster reactivation
Key clinical trials
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA (PHASE3)
- CP-690,550 Thorough QTc Study (PHASE1)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (PHASE3)
- A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (PHASE3)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (PHASE3)
- A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (PHASE2)
- A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CP-690,550 (tofacitinib) CI brief — competitive landscape report
- CP-690,550 (tofacitinib) updates RSS · CI watch RSS
- Pfizer portfolio CI